SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
LNTH

Lantheus Holdings, Inc. (LNTH)

NASDAQ: LNTH · USD
Healthcare · Drug Manufacturers - Specialty & Generic
$102.10+$0.00 (+0.00%)
 
Market cap
$6.68B
Insider Score
Analyst consensus
Market Cap$6.68B+90.5%
Revenue (ttm)$1.56B
Net Income$269.90M
EPS$4.02
Shares Out65.40M
PE Ratio25.40
Forward PE15.34
Dividendn/a
Ex-Dividend Daten/a
Volume1,067,788
Open$102.10
Previous Close$102.10
Day's Range$102.07 - $102.40
52-Week Range$54.94 - $111.86
Beta0.03
AnalystsHold
Price Target$105.99(+3.81%)
Earnings DateNov 5, 2026

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Address
201 Burlington Road, Bedford, MA, 01730, United States
Market Cap
6.68 billion
Employees
1,193
Industrial Classification
Drug Manufacturers - Specialty & Generic

Analyst consensus

Hold
0 Buy1 Hold0 SellAvg target $110.88 (+8.6%)

1 firm rating LNTH in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
+0.00%
5 Days
+0.50%
1 Month
+2.00%
6 Months
-0.87%
1 Year
+90.52%

$LNTH stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of LNTH by members of U.S. Congress

Gilbert CisnerosHouse / DSale$1.00K – $15.00KOct 15, 2026
Gilbert CisnerosHouse / DSale$1.00K – $15.00KOct 14, 2026
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KJan 28, 2025
Gilbert CisnerosHouse / DPurchase$1.00K – $15.00KJan 28, 2025
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KJan 27, 2025
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KJan 13, 2025
Gilbert CisnerosHouse / DPurchase$1.00K – $15.00KJan 13, 2025
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KJan 12, 2025

Recently reported changes in LNTH holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LNTH's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LNTH Estimated quarterly lobbying spending

Source: U.S. Senate LDA

LNTH Revenue by Segment or Geography

$779.83MTotal
Product revenue, net$378.37M48.52%
PYLARIFY$238.93M30.64%
DEFINITY$85.67M10.99%
Neuraceq$45.58M5.84%
Strategic partnerships and other revenue$19.73M2.53%
License and royalty revenues$11.55M1.48%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New LNTH patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LNTH from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from LNTH’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
51
News & Sentiment
38% of score
72

News check: Positive pipeline progress with Phase 3 Alzheimer's data presentation and strategic asset sale to strengthen core business focus.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

ZIGThe Acquirers Fund3.25%
MNANYLI Merger Arbitrage ETF3.05%
MRGRProShares - Merger ETF2.30%
ARBAltShares Merger Arbitrage ETF2.00%
GRPMInvesco S&P MidCap 400 GARP ETF1.97%
EWMCInvesco S&P MidCap 400 Equal Weight ETF1.97%
XHEState Street SPDR S&P Health Care Equipment ETF1.53%
IVSSApplied Finance IVS US SMID ETF1.06%
EVNTAltShares Event-Driven ETF0.99%
MCOWPacer Funds Trust - Pacer S&P MidCap 400 Quality FCF Aristocrats ETF0.81%
FLQSFranklin U.S. Small Cap Multifactor Index ETF0.79%
HIAIETF Opportunities Trust - Ai Funds High Conviction US Equity AI-Managed ETF0.77%

Weight is the stock’s share of each fund’s holdings.